CD270 (HVEM) Monoclonal Antibody (LH1), eBioscience™, Invitrogen™

Description

Description: The LH1 monoclonal antibody reacts with mouse Herpes Virus Entry Mediator (HVEM, TR2), a member of the TNF-receptor superfamily. HVEM is found on most cell types, including T cells, B cells, monocytes, neutrophils and dendritic cells. This receptor was identified as a cellular mediator of herpes simplex virus (HSV) entry. Binding of HSV viral envelope glycoprotein D (gD) to this receptor protein has been shown to be part of the viral entry mechanism. The cytoplasmic region of HVEM was found to bind to several TRAF family members, which may mediate the signal transduction pathways that activate the immune response. HVEM has also been demonstrated to be a unique ligand for BTLA (B and T lymphocyte attenuator). The conservation of the BTLA-HVEM interaction between mouse and human suggests that this system is an important pathway regulating lymphocyte activation and/or homeostasis in the immune response. The LH1 antibody has been reported as a blocking antibody, interfering with the HVEM-LIGHT interaction but not the HVEM-BTLA interaction. Applications Reported: This LH1 antibody has been reported for use in flow cytometric analysis and functional assays. Applications Tested: This LH1 antibody has been tested by flow cytometric analysis of mouse splenocytes. This can be used at less than or equal to 0.25 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL.

TNFRSF14 is a member of the TNF-receptor superfamily. TNFRSF14 was identified as a cellular mediator of herpes simplex virus (HSV) entry. Binding of HSV viral envelope glycoprotein D (gD) to TNFRSF14 has been shown to be part of the viral entry mechanism. The cytoplasmic region of TNFRSF14 was found to bind to several TRAF family members, which may mediate the signal transduction pathways that activate the immune response. Activation of the signal transduction pathway involving TNFRSF14 in T cells stimulates T cell proliferation and cytokine production, leading to inflammation and enhanced CTL-mediated tumor immunity, suggesting that these proteins may be useful as potential targets for controlling cellular immune responses. Multiple alternatively spliced transcript variants have been described, but the full-length nature of some of these TNFRSF14 variants have not been determined.